WMSA
ALLO icon

Weiss Multi-Strategy Advisers’s Allogene Therapeutics ALLO Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$1.35M – 507
2018
Q4 		$1.35M Buy
+50,000
New +$1.33M 0.06% 265

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ALLO Position: Q1 2019 in Review

Weiss Multi-Strategy Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2019, closing a stake of 50,000 shares — an estimated $1.35M sold.

Weiss Multi-Strategy Advisers first reported a position in ALLO in Q4 2018 and held it in 1 quarter. The position peaked at $1.35M in Q4 2018. 86 funds tracked by Wall St. Rank hold ALLO as of Q1 2019.

  • Weiss Multi-Strategy Advisers reported no remaining Allogene Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 50,000 Allogene Therapeutics shares in Q1 2019, an estimated $1.35M.
  • Weiss Multi-Strategy Advisers first reported a position in Allogene Therapeutics in Q4 2018 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Allogene Therapeutics position peaked at $1.35M in Q4 2018.
  • 86 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2019.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2019, filed 15 May 2019.